Researchers at The University of Texas at Austin, including Texas ChE’s Dr. George Georgiou and Dr. Jennifer Maynard, successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA). Part of the molecule was engineered at UT Austin before being licensed to New Jersey-based pharmaceutical company Elusys Therapeutics for further development. It will be sold under the name Anthim.

https://che.utexas.edu/2016/04/04/anthrax-treatment-engineered-texas-che-researchers-gains-fda-approval/